SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis — Stella

Home/Relapsing Remitting Multiple Sclerosis/

View on ClinicalTrials.gov

Recruiting

Back to Relapsing Remitting Multiple Sclerosis trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United Kingdom

Royal London Hospital, Barts Health NHS Foundation Trust, London, Greater London

Key details

Phase

Early testing

Sponsor

Queen Mary University of London

Collaborators

Takeda Pharmaceuticals International, Inc.

Enrollment target

~72 participants

Started

June 2020

Primary completion

July 2026

Age range

18 Years – 65 Years

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.